PetVivo Holdings, Inc. Announces Health Canada Acknowledgement of Spryng® as a Veterinary Medical Device
Rhea-AI Summary
PetVivo Holdings (OTCQX: PETV) announced that Health Canada has formally acknowledged Spryng with OsteoCushion Technology as a veterinary medical device for use in Canada. This regulatory acknowledgement is presented as a milestone in the company’s global commercialization strategy. The company said Spryng is a veterinarian-administered intra-articular injectable to support joint health and manage lameness in companion animals and equine athletes. Commercial availability in Canada is not immediate; PetVivo cited distribution setup, Canadian-specific packaging and labeling, and other operational requirements and currently anticipates potential availability in Q2 2026. Spryng is already commercially available in the United States and via select international distributors.
Positive
- Health Canada acknowledgement of Spryng as a veterinary device
- Company anticipates potential commercial availability in Q2 2026
- Spryng already commercially available in the United States
- Regulatory milestone supports global commercialization strategy
Negative
- Spryng not immediately available in Canada due to distribution setup
- Canadian-specific packaging and labeling remain to be completed
News Market Reaction – PETV
On the day this news was published, PETV gained 1.03%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
PETV gained 3.74% while key peers were mixed to negative: CSDX -8.16%, BTCY -3.45%, PYNKF -1.85%, PCHM +0.27%, GTHP 0%, indicating a stock-specific reaction to the Health Canada news.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 23 | Conference appearance | Positive | -5.1% | Announced presentation and investor meetings at DealFlow Discovery Conference. |
| Dec 16 | Product marketing | Positive | -2.5% | Released PetVivo.ai video explainer outlining platform and AI agents. |
| Nov 25 | AI platform launch | Positive | -14.1% | Detailed PetVivo.ai SaaS metrics after beta with 50 veterinary practices. |
| Nov 25 | AI platform launch | Positive | -14.1% | Announced AI platform reducing veterinary acquisition costs and projecting ARR. |
| Nov 17 | AI validation | Positive | -9.8% | Reported technical whitepaper validating AgenticPet AI framework and launch plans. |
Recent positive product and AI platform announcements were followed by negative 24-hour price reactions, suggesting a pattern of selling into news.
Over the past few months, PETV highlighted multiple growth initiatives, including AI platform launches with favorable unit economics and validation of its AgenticPet AI framework, yet each event saw negative 24h price reactions of -9.77% to -14.06%. A December conference presentation announcement and a PetVivo.ai explainer video also coincided with declines. Against this backdrop, Health Canada’s acknowledgment of Spryng as a veterinary medical device in Canada adds a new regulatory milestone focused on the company’s core joint health product line.
Market Pulse Summary
This announcement marks a key regulatory step as Health Canada acknowledged Spryng as a veterinary medical device, supporting PetVivo’s global commercialization strategy. The company does not expect immediate Canadian sales, pointing to operational work before a targeted Q2 2026 availability. Recent history shows multiple positive news items around AI platforms and conferences, so investors may watch how this tangible regulatory milestone translates into future revenue updates and execution against international distribution goals.
Key Terms
intra-articular medical
AI-generated analysis. Not financial advice.
MINNEAPOLIS, MN, Jan. 21, 2026 (GLOBE NEWSWIRE) -- PetVivo Animal Health, Inc., in cooperation with its parent PetVivo Holdings, Inc. (OTCQX: PETV; OTCID: PETVW) and affiliate PetVivo AI, Inc., an emerging biomedical device company focused on innovative medical technologies for companion animals and equine athletes, today announced that Health Canada has formally acknowledged Spryng® with OsteoCushion® Technology as a veterinary medical device for use in Canada.
Spryng is a veterinarian-administered, intra-articular injectable device developed to support joint health and aid in the management of lameness and other joint-related afflictions in animals. This regulatory acknowledgement by Health Canada represents a key milestone in the Company’s global commercialization strategy and underscores the product’s recognition by a major international regulatory authority.
“Receiving acknowledgment from Health Canada that Spryng meets the criteria for a veterinary medical device is an important endorsement of our scientific and regulatory strategy,” said John Lai, Chief Executive Officer of PetVivo Holdings, Inc. “This acknowledgment reflects our continued commitment to expanding access to innovative, safe, and effective solutions that improve the health and mobility of companion animals and athletic equines. We look forward to advancing Spryng’s availability in Canada as part of our broader global growth plan.”
While Health Canada’s acknowledgement represents an important regulatory milestone, Spryng is not expected to be immediately available in Canada due to ongoing distribution infrastructure development, Canadian-specific packaging and labeling preparations, and other operational requirements. Subject to the completion of these items, the Company currently anticipates a potential commercial availability in Canada in the second calendar quarter of 2026.
Spryng with OsteoCushion Technology has garnered interest from veterinarians and animal health partners worldwide, and this latest regulatory milestone further supports PetVivo’s efforts to bring transformative joint support solutions to the global veterinary market.
Spryng is commercially available in the United States and through select distribution partners internationally.
For more information about Spryng and PrecisePRP, please contact info1@petvivo.com or visit petvivo.com, petvivoanimalhealth.com and sprynghealth.com.
About PetVivo Holdings, Inc.
PetVivo Holdings Inc. (OTCQX: PETV; OTCID: PETVW), in cooperation with its wholly owned subsidiaries PetVivo Animal Health, Inc. and PetVivo AI Inc., is an emerging biomedical device company currently focused on the manufacturing, commercialization and licensing of innovative medical devices and therapeutics for companion animals. The Company's strategy is to leverage human therapies for the treatment of companion animals in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than more stringently regulated pharmaceuticals and biologics.
PetVivo has a robust pipeline of products for the treatment of animals and people. A portfolio of twelve patents and six trade secrets protect the Company's biomaterials, products, production processes and methods of use. The Company’s lead products SPRYNG® with OsteoCushion® technology, a veterinarian-administered, intra-articular injection for the management of lameness and other joint related afflictions, including osteoarthritis, in cats, dogs and horses, and PrecisePRP®, a first-in-class, off-the-shelf, platelet-rich plasma (PRP) product designed for use by veterinarians, are currently available for commercial sale.
Company Contact
John Lai, CEO
PetVivo Holdings, Inc.
Email Contact
Tel (952) 405-6216
Forward-Looking commercial Statements
The foregoing information regarding PetVivo Holdings, Inc. (the “Company”) may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation the Company’s proposed development and commercial timelines, and can be identified by the use of words such as “may,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,” “continue” or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to the Company and its current plans or expectations and are subject to a number of uncertainties and risks that could significantly affect current plans. Risks concerning the Company’s business are described in detail in the Company’s Annual Report on Form 10-K for the year ended March 31, 2025, and other periodic and current reports filed with the Securities and Exchange Commission. The Company is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
FAQ
What did PetVivo (PETV) announce about Spryng on January 21, 2026?
When does PetVivo expect Spryng (PETV) to become commercially available in Canada?
Why is Spryng not immediately available in Canada after Health Canada acknowledgement?
Is Spryng already sold anywhere besides Canada for PETV investors?
How does the Health Canada acknowledgement affect PetVivo’s (PETV) growth plan?
